

Launch price optimization in a crowded oncology space

Business Situation

A new-to-market pharmaceutical manufacturer needed support and justification for a proposed at-launch price range for its first product launch in the renal cell carcinoma indication.

10 9

Solution

COEUS designed and conducted an exhaustive study with a cross-functional group of payers spanning commercial, Medicare, Medicaid, IDN, PBM, GPO, and oncology mega-practices. Our research approach consisted of two phases:

PHASE 1	PHASE 2
Survey on product profile, product utilization, current contracting, and pricing parameters to establish a market-determined pricing and contracting approach	Interview survey participants to understand rationale for responses and uncover key aspects that also impact pricing and contracting approaches

Our experts conducted extensive analysis of the collected data to develop the final recommendations, such as:

- Aggregate and customer-segmented insights on expected management, competitive differentiation, perceived value, and contracting preferences
- Van Westendorp price sensitivity analysis to determine the optimal at-launch price to ensure uptake
- Word-coding analysis from qualitative follow ups for further insights on net vs gross price

Results

Leveraging our deep expertise in oncology market access, the COEUS team provided the new-to-market manufacturer with a robust pricing strategy that effectively supported their proposed price range for their first product launch in the renal carcinoma indication.

Upon concluding market research, COEUS crafted a compelling Board of Directors presentation, driving the decision for the optimal price point.

